PARISK: Molecular Imaging of Plaque Vulnerability

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02640313
Collaborator
(none)
14
1
1
51
0.3

Study Details

Study Description

Brief Summary

Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a sensitive molecular tracer for PET imaging that is taken up in activated cells and, as such, is able to identify active inflammatory sites. The investigators hypothesize that 18F-choline is also highly taken up in vulnerable plaques in comparison to the stable ones.

Condition or Disease Intervention/Treatment Phase
  • Drug: 18F-choline PET-MR imaging
Phase 3

Detailed Description

Accumulation and subsequent activation of inflammatory cells in the atherosclerotic plaques play an essential role in transforming a stable plaque into a vulnerable plaque at risk to rupture. On this basis, the study aims to evaluate the diagnostic performance of 18F-choline PET in identifying ongoing inflammation within atherosclerotic plaques. The investigators hypothesize that 18F-choline PET is efficient in detecting intraplaque inflammation and identify vulnerable plaques that are prone to rupture in comparison to the stable ones.

It is likely that by correlating the inflammatory status of an atherosclerotic plaque (on 18F-choline PET) with the presence of other vulnerable plaque features (on MR imaging) would be of high clinical relevance for clinical diagnosis of vulnerable plaques.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Molecular Imaging of Plaque Vulnerability Using 18F-choline PET-MRI in Carotid Artery Atherosclerosis Patients
Actual Study Start Date :
Dec 1, 2015
Anticipated Primary Completion Date :
Mar 1, 2020
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: 18F-choline PET-MR imaging

Intervention: 18F-choline PET-MR imaging. Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose. Procedure: dynamic and static 18F-choline PET-MR.

Drug: 18F-choline PET-MR imaging
Dynamic and static 18F-choline PET-MR imaging
Other Names:
  • PET-MRI
  • Outcome Measures

    Primary Outcome Measures

    1. 18F-choline uptake, as marker of plaque inflammation [1 year]

      • To assess on PET the uptake of 18F-choline tracer in the symptomatic carotid artery plaque, given as Target-to-Background uptake Ratio (TBR);

    2. correlate the intra-plaque uptake of 18F-choline on PET with the total area of CD68-positivity within the symptomatic plaque [1 year]

      • In case of carotid surgery, to correlate the intra-plaque uptake of 18F-choline on PET with the total area of CD68-positivity within the symptomatic plaque, as a measure of plaque inflammation and vulnerability on histology

    3. sensitivity, specificity, negative predictive value of 18F-choline PET [1 year]

      • To determine the sensitivity, specificity, negative predictive value of 18F-choline PET in diagnosis of vulnerable plaques.

    Secondary Outcome Measures

    1. Correlation of F18-Choline uptake vs other histologic plaque parameters. [1 year]

      • In case of carotid surgery, to correlate the intra-plaque 18F-choline uptake on PET with other histologic plaque parameters besides inflammation, such as the total area of intra-plaque lipid core, haemorrhage, fibrous tissue and calcifications;

    2. Correlation of F18-Choline uptake vs PET and MRI parameters of atherosclerotic plaque [1 year]

      • To correlate the intra-plaque 18F-choline uptake on PET and MRI parameters of atherosclerotic plaque, such as % of intra-plaque fibrous tissue, lipid core, hemorrhage, calcifications;

    3. Correlation of F18-choline plaque uptake vs 18F-FDG uptake [1 year]

      • To correlate the intra-plaque 18F-choline uptake on PET with the already established FDG PET imaging parameters of atherosclerotic plaque, such as inflammation;

    4. Symptomatic vs asymptomatic F18-Choline uptake [1 year]

      • To compare on PET the 18F-choline uptake in the symptomatic carotid plaque with the uptake in the asymptomatic contralateral carotid artery.

    5. Correlation of F18choline plaque uptake vs cardiovascular risk profile [1 year]

      • To evaluate a possible association between the degree of 18F-choline uptake on PET with patients' cardiovascular risk profile and medical history.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients known with symptomatic carotid artery stenosis (≥2 mm carotid plaque on duplex ultrasound), who are scheduled in the clinical setting to undergo a carotid endarterectomy or who are referred to conservative therapy;

    • Age 18 years and older (no maximum age);

    • Informed consent by signing informed consent form regarding this study.

    Exclusion Criteria:
    • Dementia, pregnancy, nursing mothers;

    • Serious neurological deficits at symptomatic side (hemi paralysis, complete aphasia);

    • Severe heart failure NYHA III-IV and severe pulmonary dysfunction dependent on oxygen supply;

    • Patients with contra-indications for MRI (ferromagnetic implants like pacemakers or other electronic implants, metallic splinters in the eyes, vascular clips, claustrophobia, etc.).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Maastricht University Medical Center Maastricht Netherlands 6229 HX

    Sponsors and Collaborators

    • Maastricht University Medical Center

    Investigators

    • Study Director: M. Eline Kooi, PhD, Maastricht University Medical Center
    • Principal Investigator: Jochem van der Pol, MD, Maastricht University Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Maastricht University Medical Center
    ClinicalTrials.gov Identifier:
    NCT02640313
    Other Study ID Numbers:
    • NL43466.068.13/ABR43466
    • NCT01899014
    First Posted:
    Dec 28, 2015
    Last Update Posted:
    Jan 25, 2019
    Last Verified:
    Jan 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Maastricht University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 25, 2019